Immunization can prevent long-term effects of meningococcal disease, such as hearing loss and psychological problems

A systematic literature review of studies of the long-term effects of invasive meningococcal disease in high-income countries found that children who survived the disease had a greater incidence of hearing loss and psychological problems, including attention-deficit/hyperactivity disorder (ADHD) than control groups or the general population. In addition, they had increased odds of death – one study showed more than a 25% greater mortality rate in this population than did the general public up to 30 years after having the disease.

The HPV vaccine can protect both young women and men from oropharyngeal cancers

HPV vaccine given to young women may also protect similarly-aged men against oropharyngeal cancers, which have been rising in incidence in the U.S. and Western Europe. In a small study in the UK, rates of oral HPV infections caused by HPV-16 were similar for males 12-24 years of age and vaccinated females (0% vs. 0.5%). This was considerably lower than the rates for unvaccinated females (5.6%) and men ≥25 years old (7.1%).

HPV-16 is the main HPV type linked to oropharyngeal cancers.

Flu vaccination in children may reduce unnecessary antibiotic prescriptions during influenza season

Among 33,000 preschool children in the UK (who received at least one prescription of amoxicillin) there were ~15% fewer amoxicillin prescriptions given during the influenza season to children who had received the live attenuated influenza vaccine than among children who were not vaccinated. This suggests that flu vaccination may lead to a reduction in excess, inappropriate prescribing of antibiotics for influenza in children.

Influenza outbreaks can have massive economic impacts

Researchers modeled the costs, using the UK’s 2004 economy, of potential pandemic flu in the UK. Costs of illness alone ranged between 0.5% and 1.0% of gross domestic product (£8.4bn to £16.8bn) for low fatality scenarios, 3.3% and 4.3% (£55.5bn to £72.3bn) for high fatality scenarios, and larger still for an extreme pandemic. Vaccination with a pre-pandemic vaccine could save 0.13% to 2.3% of gross domestic product (£2.2bn to £38.6bn); a single dose of a matched vaccine could save 0.3% to 4.3% (£5.0bn to £72.3bn), and two doses of a matched vaccine could limit the overall economic impact to about 1% of gross domestic product for all disease scenarios.